bosentan anhydrous has been researched along with cgs 26303 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, TJ; Burrell, LM; Cao, Z; Casley, D; Cooper, ME; Davis, BJ; Johnston, CI; Lassila, M; Tikkanen, I; Tikkanen, T | 1 |
| Goto, K | 1 |
1 review(s) available for bosentan anhydrous and cgs 26303
| Article | Year |
|---|---|
[Prospects for endothelin-related drugs].
Topics: Animals; Aspartic Acid Endopeptidases; Bosentan; Cardiovascular Diseases; Drug Design; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Hemodynamics; Humans; Metalloendopeptidases; Organophosphonates; Peptides, Cyclic; Quinazolines; Receptors, Endothelin; Sulfonamides; Sulfonylurea Compounds; Tetracyclines; Tetrazoles | 2004 |
1 other study(ies) available for bosentan anhydrous and cgs 26303
| Article | Year |
|---|---|
Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Aspartic Acid Endopeptidases; Atrial Natriuretic Factor; Blood Pressure; Bosentan; Diabetes Mellitus, Experimental; Drug Interactions; Endothelin Receptor Antagonists; Endothelin-Converting Enzymes; Heart; Kidney; Male; Metalloendopeptidases; Myocardium; Neprilysin; Organ Size; Organophosphonates; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Renin; Sulfonamides; Tetrazoles | 2002 |